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Human embryonic stem cells (hESCs) hold great
promise for cell therapy as a source of diverse differ-
entiated cell types. One key bottleneck to realizing
such potential is allogenic immune rejection of
hESC-derived cells by recipients. Here, we optimized
humanizedmice (Hu-mice) reconstituted with a func-
tional human immune system that mounts a vigorous
rejection of hESCs and their derivatives. We estab-
lished knockin hESCs that constitutively express
CTLA4-Ig and PD-L1 before and after differentiation,
denoted CP hESCs. We then demonstrated that allo-
genic CP hESC-derived teratomas, fibroblasts, and
cardiomyocytes are immune protected in Hu-mice,
while cells derived from parental hESCs are effec-
tively rejected. Expression of both CTLA4-Ig, which
disrupts T cell costimulatory pathways, and PD-L1,
which activates T cell inhibitory pathway, is required
to confer immune protection, as neither was suffi-
cient on their own. These findings are instrumental
for developing a strategy to protect hESC-derived
cells from allogenic immune responses without
requiring systemic immune suppression.
INTRODUCTION
Human embryonic stem cells (hESCs) can undergo unlimited
self-renewal and retain the pluripotency to differentiate into all
cell types in the body. Therefore, as a renewable source of
various cells in human body, hESCs hold great potential for
cell replacement therapy. Since the successful establishment
of hESCs in 1998 (Thomson et al., 1998), significant progress
has beenmade in establishing the conditions necessary to differ-
entiate hESCs into various lineages of biologically active cells,
including cardiomyocytes, oligodendrocytes, and pancreatic b
cells (Cohen and Melton, 2011; Fu and Xu, 2011). Despite this
tremendous progress, several major obstacles must be over-
come prior to the successful application of hESC-based cell
replacement therapies in the clinic. One such obstacle is the im-Cemune-mediated rejection of hESC-derived cells by the recipient,
because these cells are allogeneic to the recipient patients (Boyd
et al., 2012). While persistent systemic immune suppression can
delay the allograft rejection, the typical immunosuppressant
regimens are especially toxic to patients with chronic disabling
diseases (Wekerle and Grinyo´, 2012). In addition, chronic immu-
nosuppression greatly increases the risk for cancer and infection
(Gallagher et al., 2010). Therefore, to achieve the potential of
hESC-based therapy, it will be critical to develop new effective
strategies to protect hESC-derived cells from alloimmune rejec-
tion. While extensive studies on allogeneic immune responses
have been performed in mouse models, much less is known
about the human immune responses to allografts due to the
lack of relevant model system to study such human immune
responses (Zhang et al., 2009). Therefore, it is critical to develop
new models with a functional human immune system that can
mount robust alloimmune responses and mediate allograft
rejection.
Extensive effort has been devoted to developing new strate-
gies to induce immune tolerance of allogeneic transplants.
Preclinical and clinical studies indicate that induction of mixed
chimerism by transplantation of bone marrow or hematopoietic
stem cells (HSCs) can induce allograft tolerance (Ciancio et al.,
2001; Kawai et al., 2008; Tillson et al., 2006). Immature den-
dritic cells can further facilitate allogeneic HSC engraftment,
ameliorating host responses to allografts and preventing
graft-versus-host disease (GVHD) (Fugier-Vivier et al., 2005).
Considerable effort has been devoted to the potential benefits
of using these cells to induce immune tolerance to allografts
(Wood et al., 2012). Therefore, tolerance to allogeneic hESC-
derived cells could be achieved by the induction of chimerism
using hESC-derived HSCs and/or dendritic cells. If successful,
hESC-derived cells could then be transplanted without the
adverse effects of long-term immunosuppressive treatments.
However, despite a series of publications reporting the differen-
tiation of hESCs into hematopoietic progenitor cells that are
multipotent in vitro (Davis et al., 2008; Ledran et al., 2008;
Vodyanik et al., 2005; Woods et al., 2011), none of these
hESC-derived HSCs are capable of efficiently repopulating
hematopoietic lineages in mouse models. Therefore, the poten-
tial for achieving immune tolerance of hESC-derived cells by
mixed chimerism depends on the feasibility to derive authentic
HSCs from hESCs.ll Stem Cell 14, 121–130, January 2, 2014 ª2014 Elsevier Inc. 121
Cell Stem Cell
Immune Protection of hESC-Derived AllograftsCytotoxic T lymphocyte antigen 4 (CTLA4) and programmed
death ligand-1 (PD-L1) are critical immune inhibitory molecules
in maintaining peripheral tolerance by restraining T cell activity.
CTLA4 binds CD80 and CD86 with higher affinity and avidity
than CD28, which are the primary costimulation pathways for
T cell activation. Therefore, CTLA4-immunoglobulin fusion pro-
tein (CTLA4-Ig) has been developed to inhibit T cell-mediated
immune responses (Walker and Abbas, 2002). PD-L1 binds to
programmed cell death 1 (PD-1), which is expressed on T cell
surface, and this interaction inhibits T cell activity (Fife and Blue-
stone, 2008). In this context, PD-L1 plays a central role in main-
taining T cell anergy and preventing autoimmunity (Keir et al.,
2008). While data in mouse models have demonstrated the crit-
ical roles of CTLA4 and PD-L1 in suppressing allograft and xeno-
graft rejection (Fife and Bluestone, 2008; Francisco et al., 2010;
Tian et al., 2007; Walker and Abbas, 2002), the efficacy of these
immunosuppressive molecules such as CTLA4-Ig in suppress-
ing human allogeneic immune responses remains unclear as
indicated by human clinical trial data. Due to the apparent
cellular and physiological differences between mouse and
humans, much of the information on immune regulation gathered
in the mouse models cannot be completely recapitulated in
human clinical trials (Elster et al., 2004; van der Touw and Brom-
berg, 2010). By developing a humanized mouse (Hu-mouse)
model with functional human immune system that could mount
vigorous allogeneic immune rejection of hESC-derived cells,
we investigated the importance of the costimulatory pathway
and inhibitory pathway on human allogeneic immune responses.
Our findings provide a strategy to protect the hESC-derived cells
from allogeneic immune response without inducing systemic
immune suppression.
RESULTS
Developing Hu-Mice that Can Mount Vigorous
Allogeneic Immune Rejection
To examine the allogeneic immune rejection of transplanted
human cells, we established the humanized mice (Hu-mice)
reconstituted with functional human immune system by the
combined transplantation of human fetal thymus tissues and
isogenic CD34+ fetal liver cells into the immunodeficient NOD/
SCID/IL-2g/ (NSG) mice as described elsewhere (Lan et al.,
2006; Tonomura et al., 2008). Because human immune cells
develop de novo in the recipients, the human immune system
is thus tolerant of the recipient mouse and does notmediate graft
versus host reaction (Rongvaux et al., 2013; Shultz et al., 2012).
The risk to develop GVHD caused by the residue donor mature
T cells in the transplanted fetal thymus is further minimized by
one round of freeze/thaw of fetal thymus, as recently described
(Kalscheuer et al., 2012). These Hu-mice are well reconstituted
with human B and T cells (Figures 1A and 1B). In addition to
previous reports of their capability to mount antigen-specific
T cell-dependent antibody responses and mediate xenograft
rejection (Lan et al., 2006; Tonomura et al., 2008), we showed
that Hu-mice could mount effective allogeneic immune rejection
of hESC-derived cells (Figures 1C and 1D). The human leukocyte
antigen (HLA) typing information of human tissues used to repo-
pulate human immune system in mice and human ESCs was
shown in Table S1 available online. Therefore, the Hu-mouse122 Cell Stem Cell 14, 121–130, January 2, 2014 ª2014 Elsevier Inc.model is an excellent in vivo model system for studying human
immune responses against hESC-derived allografts.
Generation of CTLA4-Ig and PD-L1 Knockin hESCs
To evaluate the strategy to suppress the allogeneic immune
response by disrupting the costimulatory pathway and activating
the T cell inhibitory pathway, we designed a knockin strategy to
express the CTLA4-Ig/PD-L1 in hESC derivatives (termed CP
hESCs). To ensure the constitutive expression in hESC-derived
cells and prevent random integration that increases cancer
risk, we took advantage of a bacterial artificial chromosome
(BAC)-based targeting strategy, which can achieve high effi-
ciency of homologous recombination at the HPRT locus in
hESCs (Song et al., 2010), to insert the CAG-CTLA4-Ig-IRES-
PD-L1-PolyA expression cassette around 200 base pairs (bp)
downstream of the HPRT gene (Figures 2A and 2B). The LoxP-
flanked selection marker was inserted into the 30 untranslated
region of the HPRT gene (Figure 2B). Because HPRT is an
X-linked gene, the homologous recombination between the
targeting vector and the endogenous HPRT locus in male hESCs
led to the loss of HPRT expression, which could be easily
selected by their insensitivity to 1 mM 6-thioguanine (6-TG).
Transient expression of Cre enzyme in the targeted hESCs led
to the excision of the selection marker from the targeted allele
through LoxP/Cre-mediated deletion, leading to the normal
HPRT expression; thus, the resistance to HAT but sensitivity to
6-TG (Figures 2C and 2D). The expression and secretion of the
CTLA4-Ig dimmer by CP hESCs were confirmed by western
blotting (Figure 2E). In addition, the surface expression of PD-
L1 in CP hESCs was confirmed by flow cytometric analysis
(Figure 2F). The examination of expression of hESC-specific
pluripotency genes and surface markers and the capability to
form well-differentiated teratomas in SCID mice confirms the
pluripotent state of CP hESCs (Figure S1).
Teratomas Formed by CP hESCs Are Protected from
Allogeneic Immune Responses
To determine whether various lineages of cells derived from CP
hESCs were immune rejected by the allogeneic human immune
response, we took advantage of the capability of hESCs to form
teratomas that contain cells derived from each of the three germ
layers. CP hESCs were implanted subcutaneously into the right
flank of a Hu-mouse with an allogeneic immune system. As an
internal control, the parental hESCs were implanted into the
left flank of the same Hu-mouse. While both CP hESCs and
control parental hESCs formed teratomas in Hu-mice, the tera-
tomas formed by parental hESCs regressed rapidly (Figure 3A).
When recovered from the Hu-mice 6weeks after transplantation,
the teratomas formed by parental hESCs were much smaller
than those formed by CP hESCs and consisted primarily of liquid
cyst and few cells (Figure 3A). Because both CP hESCs and
parental hESCs could form teratomas of similar size in NSG
mice, this ruled out the possibility that the impaired teratoma
formation by the parental hESCs in Hu-mice was due to defec-
tive pluripotency of these hESCs (Figure 3A).
To test whether the teratomas formed by CP hESCs are
protected from the allogeneic immune response, the teratomas
formed by parental and CP hESCs in Hu-mice were examined
histologically. The teratoma remnant formed by parental hESCs
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Figure 1. Hu-mice Can Mount Robust Immune Rejection of hESC-Derived Allografts
(A) Representative FACS analysis of spleen, peripheral blood mononuclear cells (PBMC), and transplanted human thymus derived from Hu-mice. Single-cell
suspension was stained for the markers of human T cells (CD3, CD4, and CD8) and B cells (CD19). n > 10. Single-cell suspension derived from the spleen of NSG
mice was used as a negative control.
(B) Sections of spleens from NSG and Hu-mice were stained with hematoxylin and eosin (H&E) or with antibodies against human CD3, CD4, and CD8 and human
nuclei (HuNu) to show the repopulation of human T cells in spleen. Nuclei were counterstained with DAPI. Scale bars, 100 mm. Representative images are shown.
n = 4 for NSG group, n > 20 for Hu-mice group.
(C) NSG and Hu-mice were subcutaneously implanted with allogeneic Hues 3 and Hues 8 hESCs around the hindlegs. Six to 8 weeks after implantation,
teratomas were harvested, sectioned, and stained with anti-human CD4 and CD8 antibodies. mag, magnification.
(D) Extensive necrosis was detected in the teratomas formed by allogeneic Hues 3 and Hues 8 hESCs in Hu-mice, as revealed by hematoxylin and eosin staining.
n = 4 for the Hues 3/Hu-mice group; n = 6 for the Hues 8/Hu-mice group; n > 10 for the Hues 3/NSG group; and n > 10 for Hues 8/NSG group.
See also Table S1.
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Immune Protection of hESC-Derived Allograftsin Hu-mice was consisted mostly of liquid cysts and was exten-
sively infiltrated with human T cells, indicating robust immune
rejection (Figures 3B–3D). In contrast, the teratomas formed by
CP hESCs in Hu-mice were consisted of well-differentiated
tissues with greatly reduced T cell infiltration, indicating that cells
derived from CP hESCs were protected from the allogeneic
immune system (Figures 3B–3E). In this context, the number of
human T cells infiltrated into CP hESC-derived teratoma is
only a few percent of that in parental hESC-derived teratomas
formed in the same Hu-mouse, indicating that CP hESC-derived
teratomas can be protected from allogenic immune response
without inducing systemic immune suppression (Figure 3D).
While the percentage of CD4+CD25+Foxp3+ Treg cells in
the T cells infiltrating in the teratomas formed by CP hESCsCewas similar to that in teratomas formed by wild-type (WT)
parental hESCs, the T cells purified from the CP-derived tera-
tomas expressed significantly higher levels of immune suppres-
sive cytokines such as interleukin-10 (IL-10) and transforming
growth factor (TGF)-b than those in parental hESC-derived tera-
tomas (Figure 3F). The majority of teratomas formed by CP
hESCs in Hu-mice reached the allowed maximum size by
8 weeks after implantation; some slower growing teratomas
formed by CP hESCs were immune protected in Hu-mice for
up to 3 months when they reached the allowed maximum size.
Therefore, the greatly reduced T cell infiltration and a local
immune suppressive environment contribute to the long-term
protection of CP hESC-derived cells from allogeneic immune
rejection.ll Stem Cell 14, 121–130, January 2, 2014 ª2014 Elsevier Inc. 123
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Figure 2. Generation of Hues 3 CP hESCs
(A) The endogenous human hypoxanthine phosphoribosyltransferase 1 (HPRT1) locus. Open box indicates the 30 untranslated region of HPRT1. Filled boxes
indicate part of the HPRT1 coding sequence. The stop codon (TAA) and the binding sites of the primers used for identification of targeting clones are indicated.
(B) BAC-based targeting vector. The LoxP-flanked selection cassette was inserted between the stop codon and the PolyA signal sequence ofHPRT1 to block its
expression, introducing both positive and negative selections during targeting process. The CAG promoter-driving expression cassette, CAG/CTLA4-Ig/IRES/
PD-L1/pA, was inserted about 600 bp downstream of the HPRT1 gene. The sizes of homologous arms are indicated. IRES, internal ribosomal entry site.
(C) PCR analysis of the targeted clones in male hESCs (HUES 3). 1 and 2, two targeted clones CP-1 and CP-2; Tg, a random integration clone. The primers used
are indicated in (A) and (B).
(D) Drug sensitivity assay to confirm the expression and function of HPRT1 in the knockin clones. Cells were seeded on to 12-well plates. On the following day, the
media were changed to that containing HAT or 6-TG or without a drug. After being treated for 3 days, the cells were stained with an alkaline phosphatase
detection kit.
(E) The expression and secretion of CTLA4-Ig was confirmed. Loading buffer with or without the reducing agent b-mercaptoethanol (b-ME) was used to evaluate
the dimerization status of CTLA4-Ig.
(F) The surface expression of PD-L1 was confirmed by flow cytometry.
See also Figure S1.
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Immune Protection of hESC-Derived AllograftsIn further support of the conclusion that CP hESC-derived
teratomas are protected from allogenic immune response, the
teratomas formed by the allogeneic CP hESCs in Hu-mice
contained cells derived from each of the three germ layers (Fig-
ures 4A and 4B). In addition, the comparison of the expression of
lineage-specific genes in the teratomas formed by CP hESCs
in Hu-mice and in NSG mice further suggests that no specific
cell lineages differentiated from CP hESCs were rejected (Fig-
ure 4C). Using the same strategy, the analysis of another inde-
pendently generated CP HUES-8 hESC line further supports
the conclusion that the expression of CTLA4-Ig and PD-L1 by
the cells derived from hESCs can protect them from allogeneic
immune response (Figure S2).
To further confirm that the expression of CTLA4-Ig and PD-L1
does not induce systemic immune response, CP hESCs were124 Cell Stem Cell 14, 121–130, January 2, 2014 ª2014 Elsevier Inc.implanted into Hu-mice, the teratomas were removed
6 weeks later, and the same Hu-mice were implanted with
parental hESCs. Six to 8 weeks after implantation, the teratomas
formed by parental hESCs were recovered and analyzed for
immune rejection, indicating that the parental hESC-derived
teratomas were immune rejected with extensive infiltration
of T cells (Figure S3A). In contrast, when parental hESCs
mixed with CP hESCs at a ratio of 2:1 were injected into Hu-
mice, the resulting teratomas contained cells derived from
both WT and CP hESCs without any apparent immune rejection,
indicating that the cells derived from CP hESCs can provide
local protection of cells derived from parental hESCs from
allogeneic rejection (Figure S3B). These findings further support
the conclusion that the local expression of CTLA4-Ig and PD-L1
could achieve immune protection of hESC-derived allografts
Frequency of teratoma rejection and CD4+ T cells infiltration (%)
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Figure 3. Expression of PD-L1 and CTLA4-Ig Protects CP hESC-Derived Teratomas from Allogeneic Immune Rejection
(A) Images of teratomas derived from WT and CP hESCs formed in Hu-mice and NSG mice. Mice were subcutaneously injected with WT hESCs and CP hESCs
around the left and right hindlegs, respectively. Six to 8 weeks after implantation, the mice were euthanized and teratomas were examined. Representative
images are shown.
(B) Extensive tissue necrosis was detected in the teratomas formed by WT hESCs in Hu-mice.
(C and D) Significant T cell infiltration was detected in the teratomas formed by WT hESCs but not those formed by CP hESCs in Hu-mice, as shown by
immunohistochemistry (C) and flow cytometry (D).
(E) Summary of teratoma formation, immune rejection, and CD4+ T cell infiltration. Teratomas with apparent regressing phenotype or containing only liquid-filled
cysts without cell mass were classified as rejection.
(F) Relative mRNA levels of IL-10, TGF-b1, and IL-2 in T cells isolated from CP hESC- and WT hESC-derived teratomas formed in the same Hu-mouse were
determined by real-time PCR. Mean values are presented with SD (n = 3).
See also Figures S2 and S3.
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Immune Protection of hESC-Derived Allograftswithout inducing systemic immune suppression or immune
tolerance.
Cells Derived from CP hESCs Are Protected from
Allogeneic Immune Response
To further evaluate the immune response to hESC-derived cells,
human fibroblasts and cardiomyocytes were derived from CP
and control parental hESCs, with their identities confirmed by
cell-type-specific gene expression (Figures S4C–S4G). The CP
hESC-derived cells were confirmed for the expression of
CTLA4-Ig and PD-L1 (Figure S4B). In addition, the increased
expression of HLA class I on the differentiated cell types was
confirmed by real-time PCR assay (Figure S4A). Consistent
with previous findings (Blo¨mer et al., 2005; Xu et al., 2008), the
hESC-derived cardiomyocytes could survive for an extended
period of time in vivo after being transplanted into the hind leg
muscle of NSG mice (Figure S4F). For control WT and CP
hESC-derived fibroblasts, they were embedded into gel foam
and implanted into the left and right sides of the same Hu-mice
subcutaneously (Figure 5A). For control and CP hESC-derivedCecardiomyocytes, they were injected directly into the skeletal
muscle of the left and right hind legs of Hu-mice (Figures 5B
and 5C). While significant T cell infiltration was detected in the
parental hESC-derived cells transplanted in Hu-mice, greatly
reduced T cell infiltration was detected in the graft of CP
hESC-derived cells in the same Hu-mice, indicating that CP
hESC-derived fibroblasts and cardiomyocytes were also
protected from the allogeneic immune response (Figure 5).
Therefore, these data demonstrate that somatic cells differenti-
ated from CP hESCs are protected from allogeneic human im-
mune system.
Dissecting the Contribution of CTLA4-Ig and PD-L1 to
Immune Protection
To determine the contribution of CTLA4-Ig and PD-L1 to the
immune protection of hESC-derived allografts, we used the
same knockin strategy to introduce the CTLA4-Ig and PD-L1
expression cassette independently into the HPRT locus of
hESCs (Figure S5). Once confirmed for their pluripotency and
the expression of CTLA4-Ig or PD-L1 (Figure S5), the parentalll Stem Cell 14, 121–130, January 2, 2014 ª2014 Elsevier Inc. 125
Figure 4. Various Lineages of Cells Derived
from CP hESCs Are Protected from Alloge-
neic Immune Rejection
(A) Various cell lineages were present in the
teratomas formed by CP hESCs in Hu-mice. SE,
squamous epithelium; R, rosette; B, bone; C,
cartilage; H, hepatocyte-like cells; GE, gut-like
epithelium.
(B) Established teratomas formed by CP hESCs
in Hu-mice contained various cell lineages indi-
cated by immunohistochemical staining. NeuN,
neuronal marker; C-peptide, pancreatic b cell
marker; Keratin, panepidermis marker.
(C) The relative expression levels of the three germ
layer-specific genes in teratomas formed by CP
hESCs derived from NSG and Hu-mice. Mean
values are presented with SD (for NSGmice, n = 7;
for Hu-mice, n = 12).
Cell Stem Cell
Immune Protection of hESC-Derived Allograftsand knockin hESCs were transplanted subcutaneously into the
left and right flanks of Hu-mice. In contrast to the teratomas
formed by CP hESCs that are protected from allogeneic immune
system in Hu-mice, teratomas formed by knockin hESCs
expressing only CTLA4-Ig or PD-L1 were robustly immune re-
jected in Hu-mice, similarly to the teratomas formed by parental
hESCs (Figures 6A–6C). Therefore, CTLA4-Ig and PD-L1 must
work together to protect the transplanted cells from the alloge-
neic immune responses.
DISCUSSION
Since the successful establishment of hESCs in 1998 (Thomson
et al., 1998), tremendous progress has been achieved in gener-
ating Good Manufacturing Practice (GMP)-grade hESC lines, in
large-scale hESC production, and in the lineage-specific differ-
entiation of hESCs (Fu and Xu, 2011). In addition, the feasibility
of hESC-based human cell therapy is further supported by the
initiation of two phase I clinic trials of hESC-based cell therapy
of spinal cord injury and macular degeneration (Schwartz et al.,
2012; Wirth et al., 2011). However, one major hurdle that hinders
the clinic development of hESC-based cell therapy is the alloge-
neic immune rejection of hESC-derived cells by the recipients,
even when the cells are transplanted into immune privileged
sites due to the breakdown of the blood-brain barrier at the
lesion site (Boyd et al., 2012). Therefore, to improve the feasibility
of hESC-based cell therapy, it is important to develop effective
and scalable approaches to protect hESC-derived allografts
from immune rejection.
In this study, we demonstrated that a Hu-mouse model recon-
stituted with functional human immune system could mount
allogeneic immune response to hESC-derived allograft. There
has been limited effort to study the human allogeneic immune
responses in vivo due to the lack of physiologically relevant
model systems. While extensive studies of transplantation
immunology in mouse models have been instrumental in
designing immune tolerance strategies in humans, an apparent
difference between mouse and human immunity has led to the
common dilemma that the findings from mouse models cannot
be recapitulated by humans (Haley, 2003; Mestas and Hughes,
2004). This bottleneck has significantly hindered the effort to
develop effective immune tolerance approaches in humans. To126 Cell Stem Cell 14, 121–130, January 2, 2014 ª2014 Elsevier Inc.address this issue, significant effort has been made to improve
Hu-mouse models with human immune system during the past
3 decades (Rongvaux et al., 2013; Shultz et al., 2012). Here,
we optimized the Hu-mouse model as a physiologically relevant
surrogate to study human allogeneic immune response. In this
study, we used Hu-mice to identify a combination of immune
regulatory molecules to effectively protect hESC-derived grafts
from allogenic immune responses. These findings are instru-
mental for developing an effective immune tolerance strategy
without inducing systemic immune suppression.
Standard immune suppressant regiments are effective for
preventing immune rejection of allogeneic organs, and their
use is justified in the case of terminally ill patients (Selzner
et al., 2010). However, the high toxicity of the immunosuppres-
sant regiments and the increased risk of spontaneous cancer
and infection associated with systemic immune suppression
significantly raise the risk/benefit ratio of hESC-based cell ther-
apy. Our strategy described here could help to mitigate these
problems by inducing local immune protection of hESC-derived
cells without using standard immune suppressants or systemic
immune suppression. However, one potential risk of this
approach is that it allows the grafted cells with tumorigenic
potential or viral infection to escape immune surveillance. One
feasible way to address this risk is to introduce a suicidal thymi-
dine kinase (TK) gene into the CTLA4-Ig/PD-L1 expression
cassette so that the transplanted cells can be effectively elimi-
nated by ganciclovir if needed (Springer and Niculescu-Duvaz,
2000). In support of this notion, we and others have reported
that TK-expressing tumors derived from hESCs could be effec-
tively eliminated in vivo by administration of ganciclovir (Cheng
et al., 2012; Rong et al., 2012; Schuldiner et al., 2003).
In the context of clinic development, the high targeting
efficiency to generate CP hESC lines supports the feasibility to
genetically modify any clinic-grade hESCs under the GMP
conditions. While the genetic modification of hESCs is a known
safety concern in human therapy associated with random inte-
gration of the exogenous DNA into the human genome, the
knockin approach used here should minimize such risk because
homologous recombination can be achieved without any
apparent random integration of the exogenous DNA (Howden
et al., 2011; Song et al., 2010). To further address this concern
before clinic application of the genetically modified hESCs, the
CD
BA
H
u-
m
ic
e 
/ W
T
H
u-
m
ic
e 
/ C
P
N
S
G
 / 
W
T
N
S
G
 / 
C
P
CD3 DAPI HuNu DAPI
Fibroblast Cardiomyocyte
CD3 DAPI HuNu DAPI
Cardiomyocyte
CD3 cTnI CD3 cTnI DAPI
0%
20%
40%
60%
WT CP WT CP
C
D
3+
/H
uN
u+
 c
el
ls
_
Cardiomyocyte
Fibroblast
Figure 5. Fibroblasts and Cardiomyocytes Derived from CP hESCs Are Protected from Allogeneic Immune Rejection in Hu-mice
(A and B) Fibroblasts (A) or cardiomyocytes (B) derived from WT and CP hESCs were transplanted into the same Hu-mice or NSG mice. Two weeks later, the
grafts were recovered and stainedwith indicated antibodies. T cells were identified by anti-CD3 antibody, and human cells in the grafts were identified by a human
nuclei (HuNu)-specific antibody. Representative images are shown. Parental WT and CP hESC-derived grafts in NSG mice were stained as negative controls.
Nuclei were counterstained with DAPI. Scale bars, 50 mm. n = 3 per group.
(C) hESC-derived cardiomyocyte allografts transplanted in Hu-mice were sectioned and stained for T cells (CD3+) and human cardiomyocytes (cTnl+), indicating
the presence of cardiomyocytes but the lack of infiltrating T cells in the CP hESC-derived cardiomyocyte allografts.
(D) Quantification of T cells infiltrated into fibroblast and cardiomyocyte allografts transplanted into Hu-mice. CD3+ and HuNu+ cells in three randomly selected
view fields were counted. The ratio of CD3+ to HuNu+ cells was used to quantify for T cell infiltration. Mean values are presented with SD (n = 3).
See also Figure S4.
Cell Stem Cell
Immune Protection of hESC-Derived Allograftsentire genome of CP hESCs will be sequenced to confirm that
no other mutations or random insertion of exogenous DNA are
introduced during homologous recombination. In summary, the
genetic approach described here could be instrumental for
developing, in the future, a safe approach to effectively protect
hESC-derived cells from allogeneic immune rejection without
inducing systemic immune suppression.EXPERIMENTAL PROCEDURES
Construction of BAC-Based Targeting Vector
The HPRT1 BAC clone RP11-671P4 was purchased from Invitrogen, and the
targeting vector was constructed by recombineering as described elsewhere
(Rong et al., 2012; Song et al., 2010). Briefly, the pCAG/CTLA4-Ig/IRES/PD-
L1/polyA expression cassette was inserted 600 bp downstream of the
HPRT1 stop codon. The Loxp-flanked selection cassette pCAG/Neo/IRES/
Puro/polyA was inserted between the HPRT1 stop codon and its endogenous
polyA site. The Cre-mediated deletion of the selection cassette will restore the
normal expression of HPRT.
Cell Culture
The hESC lines, HUES-3 and HUES-8, were cultured on mouse embryonic
fibroblast feeder layer in knockout Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% knockout serum replacement, 10% plasma-
nate, 0.1 mM nonessential amino acids, 2 mM Glutamax, 1% penicillin/Cestreptomycin, 10 ng/ml basic fibroblast growth factor, and 55 mM b-mercap-
toethanol. HUES hESCs were dissociated with TrypLE (Life Technologies)
and passaged on feeder with 1:4–1:6 dilution. All tissue culture reagents
were purchased from Invitrogen unless indicated otherwise.
HAT and 6-TG Cytotoxicity Assays
hESCs were plated on a 12-well plate, and 24 hr later, media were replaced
with that containing 100 mMhypoxanthine/0.4 mMaminopterin/6 mM thymidine
(HAT, Sigma) or 6-TG (Sigma), or weremock treated. After 3 days of treatment,
the cells were stained with an alkaline phosphatase detection kit according to
the manufacturer’s instruction (Millipore).
Flow Cytometric Analysis
The flow cytometric analysis of the surface expression of hESC-specific
markers, TRA 1-61, TRA 1-81, SSEA3, and SSEA4, was analyzed as described
elsewhere (Rong et al., 2012). Briefly, 53 105 cells were washed with PBS and
stained for 1 hr at room temperature with primary antibody. After beingwashed
twice with PBS, the cells were stained with a fluorescein isothiocyanate (FITC)/
phycoerythrin (PE)-conjugated secondary antibody for 30min at room temper-
ature and analyzed by a BD LSR-II machine using FACS Diva software (Becton
Dickinson). For flow cytometric analysis of spleen and thymus in Hu-mouse, a
single-cell suspension was mashed through 40 mM cell strainers and washed
with PBS. Red blood cells in spleen samples were removed with ACK lysis
buffer (Lonza). The primary antibodies used were as follows: anti-PD-L1 anti-
body (29E.2A3, Biolegend), PE-anti-hCD3 (eBioScience), FITC-anti-hCD19
(eBioScience), PE-anti-hCD4 (BD PharMingen), and FITC-anti-hCD8 (BD
PharMingen).ll Stem Cell 14, 121–130, January 2, 2014 ª2014 Elsevier Inc. 127
Frequency of teratoma rejection and CD4+ T cells infiltration (%)
Cell lines injected : Host Tumor 
Formation
Tumor
Rejection
Intensive CD4+ T cells
Infiltration
WT : Hu-Mice 8/8 (100) 8/8 (100) 8/8 (100)
PD-L1-KI : Hu-Mice 4/4 (100) 4/4 (100) 4/4 (100)
CTLA4-Ig-KI : Hu-Mice 4/4 (100) 4/4 (100) 4/4 (100)
WT : NSG 4/4 (100) 0/4 (0) 0/4 (0)
PD-L1-KI : NSG 3/3 (100) 0/3 (0) 0/3 (0)
CTLA4-Ig-KI : NSG 3/3 (100) 0/3 (0) 0/3 (0)
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Figure 6. Expression of PD-L1 or CTLA4-Ig
Alone Cannot Protect the Derivatives of
hESCs from Allogeneic Immune Rejection
(A) Extensive T cell infiltration was detected in the
teratomas formed by WT hESCs, PD-L1-KI-
hESCs, and CTLA4-Ig-KI-hESCs in Hu-mice.
T cells were identified by anti-CD4, anti-CD8, and
anti-CD3 antibodies.
(B) Extensive necrosis was detected in the tera-
tomas derived from WT hESCs, PD-L1-KI-hESCs,
and CTLA4-Ig-KI-hESCs in allogeneic Hu-mice, as
revealed by hematoxylin and eosin staining.
(C) The frequency of CD4+ T cell infiltration and
teratoma rejection in Hu-mice transplanted with
parental and various knockin hESCs.
See also Figure S5.
Cell Stem Cell
Immune Protection of hESC-Derived AllograftsWestern Blotting Assay
To analyze the expression of CTLA4-Ig by CP hESCs and their derivatives,
the cells were grown to confluence and the media were replaced with
DMEM basal media. Twenty-four hours later, two aliquots of the media were
harvested, boiled in 1 3 loading buffer with or without b-mercaptoethanol,
and fractionated by SDS-PAGE and transferred to nitrocellulose membrane.
After blocked with 10% milk for 45 min at room temperature, the membrane
was probed with a horseradish peroxidase (HRP)-conjugated goat anti-human
immunoglobulin G-Fc antibody (Bethyl) overnight at 4C and developed with
an enhanced chemilluminescent substrate (Pierce).
Hu-mice with Functional Human Immune System
After conditioning with sublethal (2.25 Gy) total body irradiation, NOD.Cg-
Prkdcscid Il2rgtm1wjl/SzJ (NSG; The Jackson Laboratory) mice of 6–10 weeks
of age were transplanted with a human fetal thymic tissue piece (previously
frozen at about 1mm3) under the kidney capsule, and intravenously transfused
1–5 3 105 human CD34+ fetal liver cells as described elsewhere (Lan et al.,
2006). Human fetal tissues of gestational age of 17–20 weeks were obtained
from Advanced Bioscience Resource. Human CD34+ cells were isolated by
a magnetic-activated cell sorter separation system using anti-CD34 microbe-
ads (Miltenyi Biotec).
All mouse work was approved by the Institutional Animal Care and Use
Committee of University of California, San Diego. The hESC work was
approved by the Institutional Embryonic Stem Cell Research Oversight Com-
mittee andHumanResearch Protection Program of the University of California,
San Diego.
Immunohistochemical and Histologic Analysis
Teratoma was fixed in 10% (w/v) buffered formalin, embedded in paraffin, and
sectioned as described elsewhere (Zhao et al., 2011). Briefly, the sections
were stained with hematoxylin and eosin for histological assessment and128 Cell Stem Cell 14, 121–130, January 2, 2014 ª2014 Elsevier Inc.stained with anti-NeuN (Millipore), anti-C-peptide
(Abcam), and anti-karetin (Millipore) antibodies
for immunohistochemistry analysis. For frozen
sections, samples were frozen in optimal cutting
temperature compound and sectioned. Teratoma
sections were fixed in cold acetone for 10 min
and sequentially blocked with 0.03% H2O2 for
30 min, 0.1% avidin for 15 min, 0.01% biotin for
15 min, and 1% BSA for 30 min. Sections were
incubated with primary antibody overnight at
4C, biotinylated secondary antibody for 30 min,
and HRP streptavidin for 30 min and were devel-
oped with aminoethyl carbazole substrate solu-
tion. After being counterstained with hematoxylin,
sections were mounted in aqueous gel Vecta-
mount (Vector). Images were captured with an
Olympus MVX10 Microscope or an Olympus Fluo-View 1000 Confocal Microscope. Antibodies used were as follows: anti-CD3
antibodies (Epitomics, eBioScience); anti-CD4 and anti-CD8 antibodies (BD
Pharmingen); anti-human nuclei antibody (Millipore); anti-a-actinin antibody
(Sigma); and anti-cardiac Troponin I antibody (Epitomics).
Differentiation of hESCs into Cardiomyocytes
We used a small molecule-driven cardiomyocyte differentiation protocol (Lian
et al., 2012). hESCs were maintained on a matrigel-coated plate. When
the culture reached confluence, cells were plated with GSK3 inhibitor
CHIR99021 in RPMI/B27-insulin (without insulin) medium for 24 hr (day 0 to
day 1) and subsequently changed to RPMI/B27-insulin. On day 3, the cells
were exposed to IWP4 (Stemgent) for 2 days. From day 7, the cells were
cultured in RPMI/B27 medium with medium change every 3 days.
Transplantation of hESC-Derived Fibroblasts and Cardiomyocytes
Derivation of human fibroblasts from the teratomas formed by hESCs was
performed as described elsewhere (Rong et al., 2012). Human fibroblasts
were harvested and washed with PBS. About 20 ml of fibroblast suspension
(1 3 107 cells) was loaded on to gelatin foam discs (Gelfoam, Pfizer)
(6–7 mm diameter 3 1.5 mm thick) that were prewetted with DMEM basal
media. The cells were overlaid with 15–25 ml Matrigel (BD Biosciences) and
implanted subcutaneously with cells facing the dermis. hESC-derived cardio-
myoctes were harvested, washed with PBS, suspended in PBS with 50%
Matrigel, and intramuscularly injected into the hind leg gastrocnemius with a
20G needle.
Quantitative Real-Time PCR Analysis
The total RNA was purified from hESCs, human T cells isolated from teratoma,
hESC-derived fibroblasts, and cardiomyocytes as described elsewhere (Rong
et al., 2012). The primers used for hESC markers (NANOG, OCT4, SOX2,
LIN28, REX1, TDGF-1, GABRB3, and DNMT3B), fibroblast markers
Cell Stem Cell
Immune Protection of hESC-Derived Allografts(VIMENTIN and FAP), and internal control (GAPDH) were as described else-
where (Rong et al., 2012). The primers used for cardiomyocyte markers
(NKX2.5, ISL1, MYL7, and SIRPA) were as described elsewhere (Dubois
et al., 2011). Other primers used were listed in Table S2.
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